Sleep Medicine
Sleep Medicine Clinical Trials require precise and sensitive approaches due to the complexity and multifaceted nature of sleep disorders.
These conditions often involve intricate interactions between neurological, psychiatric, respiratory, and metabolic systems. Accurate diagnostic methodologies, sophisticated sleep assessment tools, and thorough safety monitoring are essential for developing effective treatments. At iNGENū CRO, we specialise in providing meticulous, high-quality, and cost-effective clinical trial solutions tailored for the complexities inherent in sleep medicine. iNGENū CRO collaborates closely with leading sleep specialists and utilises advanced technologies such as polysomnography (PSG), actigraphy, and patient-reported outcome measures (PROMs) to ensure accurate and reliable assessments.
Our clinical team has significant experience across a range of sleep disorders, including:
- Insomnia
- Obstructive Sleep Apnoea (OSA)
- Narcolepsy
- Restless Legs Syndrome (RLS)
- Idiopathic Hypersomnia
- Circadian Rhythm Sleep-Wake Disorders
- REM Sleep Behaviour Disorder
Disciplined,
Cost-Efficient Execution
while maintaining the Highest Quality
Local Trials,
Global Approvals
Access FDA Regulatory Expertise
Our Clinical Team has over
120
years
of Combined Clinical Trial Experience
Sleep Medicine Clinical Trial Resources
Idiopathic Hypersomnia
Overcoming Challenges in Endpoint Determination and Protocol Design for Idiopathic Hypersomnia Clinical Trials.
Narcolepsy
Explore clinical trial insights and innovations in advancing Narcolepsy Clinical Research.
Narcolepsy Studies
Narcolepsy and excessive daytime sleepiness trials with wakefulness-promoting agents.
Addressing Common Pain Points Associated with Sleep Medicine Clinical Trials
Standardisation of Sleep Measurements
Problem:
Sleep assessments such as polysomnography (PSG) and actigraphy require highly controlled environments and can vary widely between sites.
iNGENū CRO addresses this pain point with Centralised and Standardised Assessments:
We employ centralised sleep laboratories with uniform protocols and extensively trained technicians to ensure consistency across trial sites. Centralised scoring by expert sleep technologists further enhances data accuracy and reliability.
Placebo Effects and Treatment Expectancy
Problem:
Sleep disorders often show significant placebo effects due to the subjective nature of sleep quality and daytime functioning assessments.
iNGENū CRO addresses this pain point with Rigorous Blinding and Trial Design:
We utilise rigorous double-blind methodologies and innovative trial designs, including crossover and placebo run-in periods, to minimise placebo and expectancy effects. Advanced statistical methods further isolate genuine treatment responses from placebo effects.
Complexity in Outcome Measures
Problem:
Evaluating sleep interventions often involves both objective measures (e.g., sleep latency, sleep architecture) and subjective measures (e.g., patient-reported sleep quality, daytime sleepiness).
iNGENū CRO addresses this pain point with Integrated Objective and Subjective Assessments:
Our trials are designed to integrate comprehensive objective measurements from PSG and actigraphy with validated subjective patient-reported outcomes (PROMs) such as the Epworth Sleepiness Scale (ESS) and Insomnia Severity Index (ISI). Expert biostatistical analysis ensures precise interpretation of multifaceted data sets.
Patient Recruitment and Retention
Problem:
Identifying and maintaining patient participation in sleep studies can be difficult due to the frequent need for overnight assessments, intrusive monitoring, and stringent eligibility criteria.
iNGENū CRO addresses this pain point with Patient-centric Approaches:
We streamline recruitment by collaborating with specialised sleep clinics and employing comprehensive patient databases. Our patient-centric trial designs incorporate home-based and remote monitoring technologies, reducing the burden on patients and enhancing retention rates.
Safety Monitoring for CNS-active Treatments
Problem:
Many sleep interventions involve central nervous system (CNS)-active treatments, which require vigilant safety monitoring due to potential adverse cognitive, behavioural, or respiratory effects.
iNGENū CRO addresses this pain point with Robust Safety Protocols:
Our dedicated safety monitoring teams conduct continuous, real-time evaluations of patient safety data. Comprehensive risk management plans and transparent communication with stakeholders ensure swift identification and handling of adverse events, prioritising patient well-being throughout the trial.
The iNGENū CRO Difference
Local Trials, Global Approvals
We uniquely combine Australian expertise with direct FDA submission capabilities.
Disciplined, Cost-Efficient Execution
iNGENū CRO takes a highly strategic approach to clinical research.
Australian-Headquartered, Asia-Pacific Reach
We provide sponsors with comprehensive trial capabilities.
We have been using iNGENū for a Phase 1, first-in-human trial of our investigational drug. We have been very happy with all aspects of the management of the clinical trial.
Ready to discuss your Sleep Medicine Clinical Trial?